MLL-fusion-driven leukemia requires SETD2 to safeguard genomic integrity

Anna Skucha, Jessica Ebner, Johannes Schmöllerl, Mareike Roth, Thomas Eder, Adrián César-Razquin, Alexey Stukalov, Sarah Vittori, Matthias Muhar, Bin Lu, Martin Aichinger, Julian Jude, André C. Müller, Balázs Gyorffy, Christopher R. Vakoc, Peter Valent, Keiryn L. Bennett, Johannes Zuber, Giulio Superti-Furga, Florian Grebien

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

MLL-fusions represent a large group of leukemia drivers, whose diversity originates from the vast molecular heterogeneity of C-terminal fusion partners of MLL. While studies of selected MLL-fusions have revealed critical molecular pathways, unifying mechanisms across all MLL-fusions remain poorly understood. We present the first comprehensive survey of protein-protein interactions of seven distantly related MLL-fusion proteins. Functional investigation of 128 conserved MLL-fusion-interactors identifies a specific role for the lysine methyltransferase SETD2 in MLL-leukemia. SETD2 loss causes growth arrest and differentiation of AML cells, and leads to increased DNA damage. In addition to its role in H3K36 tri-methylation, SETD2 is required to maintain high H3K79 di-methylation and MLL-AF9-binding to critical target genes, such as Hoxa9. SETD2 loss synergizes with pharmacologic inhibition of the H3K79 methyltransferase DOT1L to induce DNA damage, growth arrest, differentiation, and apoptosis. These results uncover a dependency for SETD2 during MLL-leukemogenesis, revealing a novel actionable vulnerability in this disease.

Original languageEnglish
Article number1983
JournalNature Communications
Volume9
Issue number1
DOIs
Publication statusPublished - Dec 1 2018

Fingerprint

leukemias
integrity
Leukemia
Fusion reactions
fusion
Methyltransferases
Methylation
DNA Damage
Proteins
methylation
Critical Pathways
Growth
proteins
Lysine
Cell Differentiation
deoxyribonucleic acid
Apoptosis
damage
vulnerability
lysine

ASJC Scopus subject areas

  • Chemistry(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Physics and Astronomy(all)

Cite this

Skucha, A., Ebner, J., Schmöllerl, J., Roth, M., Eder, T., César-Razquin, A., ... Grebien, F. (2018). MLL-fusion-driven leukemia requires SETD2 to safeguard genomic integrity. Nature Communications, 9(1), [1983]. https://doi.org/10.1038/s41467-018-04329-y

MLL-fusion-driven leukemia requires SETD2 to safeguard genomic integrity. / Skucha, Anna; Ebner, Jessica; Schmöllerl, Johannes; Roth, Mareike; Eder, Thomas; César-Razquin, Adrián; Stukalov, Alexey; Vittori, Sarah; Muhar, Matthias; Lu, Bin; Aichinger, Martin; Jude, Julian; Müller, André C.; Gyorffy, Balázs; Vakoc, Christopher R.; Valent, Peter; Bennett, Keiryn L.; Zuber, Johannes; Superti-Furga, Giulio; Grebien, Florian.

In: Nature Communications, Vol. 9, No. 1, 1983, 01.12.2018.

Research output: Contribution to journalArticle

Skucha, A, Ebner, J, Schmöllerl, J, Roth, M, Eder, T, César-Razquin, A, Stukalov, A, Vittori, S, Muhar, M, Lu, B, Aichinger, M, Jude, J, Müller, AC, Gyorffy, B, Vakoc, CR, Valent, P, Bennett, KL, Zuber, J, Superti-Furga, G & Grebien, F 2018, 'MLL-fusion-driven leukemia requires SETD2 to safeguard genomic integrity', Nature Communications, vol. 9, no. 1, 1983. https://doi.org/10.1038/s41467-018-04329-y
Skucha A, Ebner J, Schmöllerl J, Roth M, Eder T, César-Razquin A et al. MLL-fusion-driven leukemia requires SETD2 to safeguard genomic integrity. Nature Communications. 2018 Dec 1;9(1). 1983. https://doi.org/10.1038/s41467-018-04329-y
Skucha, Anna ; Ebner, Jessica ; Schmöllerl, Johannes ; Roth, Mareike ; Eder, Thomas ; César-Razquin, Adrián ; Stukalov, Alexey ; Vittori, Sarah ; Muhar, Matthias ; Lu, Bin ; Aichinger, Martin ; Jude, Julian ; Müller, André C. ; Gyorffy, Balázs ; Vakoc, Christopher R. ; Valent, Peter ; Bennett, Keiryn L. ; Zuber, Johannes ; Superti-Furga, Giulio ; Grebien, Florian. / MLL-fusion-driven leukemia requires SETD2 to safeguard genomic integrity. In: Nature Communications. 2018 ; Vol. 9, No. 1.
@article{7e1391104b764502bc11f409e09eef5d,
title = "MLL-fusion-driven leukemia requires SETD2 to safeguard genomic integrity",
abstract = "MLL-fusions represent a large group of leukemia drivers, whose diversity originates from the vast molecular heterogeneity of C-terminal fusion partners of MLL. While studies of selected MLL-fusions have revealed critical molecular pathways, unifying mechanisms across all MLL-fusions remain poorly understood. We present the first comprehensive survey of protein-protein interactions of seven distantly related MLL-fusion proteins. Functional investigation of 128 conserved MLL-fusion-interactors identifies a specific role for the lysine methyltransferase SETD2 in MLL-leukemia. SETD2 loss causes growth arrest and differentiation of AML cells, and leads to increased DNA damage. In addition to its role in H3K36 tri-methylation, SETD2 is required to maintain high H3K79 di-methylation and MLL-AF9-binding to critical target genes, such as Hoxa9. SETD2 loss synergizes with pharmacologic inhibition of the H3K79 methyltransferase DOT1L to induce DNA damage, growth arrest, differentiation, and apoptosis. These results uncover a dependency for SETD2 during MLL-leukemogenesis, revealing a novel actionable vulnerability in this disease.",
author = "Anna Skucha and Jessica Ebner and Johannes Schm{\"o}llerl and Mareike Roth and Thomas Eder and Adri{\'a}n C{\'e}sar-Razquin and Alexey Stukalov and Sarah Vittori and Matthias Muhar and Bin Lu and Martin Aichinger and Julian Jude and M{\"u}ller, {Andr{\'e} C.} and Bal{\'a}zs Gyorffy and Vakoc, {Christopher R.} and Peter Valent and Bennett, {Keiryn L.} and Johannes Zuber and Giulio Superti-Furga and Florian Grebien",
year = "2018",
month = "12",
day = "1",
doi = "10.1038/s41467-018-04329-y",
language = "English",
volume = "9",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - MLL-fusion-driven leukemia requires SETD2 to safeguard genomic integrity

AU - Skucha, Anna

AU - Ebner, Jessica

AU - Schmöllerl, Johannes

AU - Roth, Mareike

AU - Eder, Thomas

AU - César-Razquin, Adrián

AU - Stukalov, Alexey

AU - Vittori, Sarah

AU - Muhar, Matthias

AU - Lu, Bin

AU - Aichinger, Martin

AU - Jude, Julian

AU - Müller, André C.

AU - Gyorffy, Balázs

AU - Vakoc, Christopher R.

AU - Valent, Peter

AU - Bennett, Keiryn L.

AU - Zuber, Johannes

AU - Superti-Furga, Giulio

AU - Grebien, Florian

PY - 2018/12/1

Y1 - 2018/12/1

N2 - MLL-fusions represent a large group of leukemia drivers, whose diversity originates from the vast molecular heterogeneity of C-terminal fusion partners of MLL. While studies of selected MLL-fusions have revealed critical molecular pathways, unifying mechanisms across all MLL-fusions remain poorly understood. We present the first comprehensive survey of protein-protein interactions of seven distantly related MLL-fusion proteins. Functional investigation of 128 conserved MLL-fusion-interactors identifies a specific role for the lysine methyltransferase SETD2 in MLL-leukemia. SETD2 loss causes growth arrest and differentiation of AML cells, and leads to increased DNA damage. In addition to its role in H3K36 tri-methylation, SETD2 is required to maintain high H3K79 di-methylation and MLL-AF9-binding to critical target genes, such as Hoxa9. SETD2 loss synergizes with pharmacologic inhibition of the H3K79 methyltransferase DOT1L to induce DNA damage, growth arrest, differentiation, and apoptosis. These results uncover a dependency for SETD2 during MLL-leukemogenesis, revealing a novel actionable vulnerability in this disease.

AB - MLL-fusions represent a large group of leukemia drivers, whose diversity originates from the vast molecular heterogeneity of C-terminal fusion partners of MLL. While studies of selected MLL-fusions have revealed critical molecular pathways, unifying mechanisms across all MLL-fusions remain poorly understood. We present the first comprehensive survey of protein-protein interactions of seven distantly related MLL-fusion proteins. Functional investigation of 128 conserved MLL-fusion-interactors identifies a specific role for the lysine methyltransferase SETD2 in MLL-leukemia. SETD2 loss causes growth arrest and differentiation of AML cells, and leads to increased DNA damage. In addition to its role in H3K36 tri-methylation, SETD2 is required to maintain high H3K79 di-methylation and MLL-AF9-binding to critical target genes, such as Hoxa9. SETD2 loss synergizes with pharmacologic inhibition of the H3K79 methyltransferase DOT1L to induce DNA damage, growth arrest, differentiation, and apoptosis. These results uncover a dependency for SETD2 during MLL-leukemogenesis, revealing a novel actionable vulnerability in this disease.

UR - http://www.scopus.com/inward/record.url?scp=85047193516&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047193516&partnerID=8YFLogxK

U2 - 10.1038/s41467-018-04329-y

DO - 10.1038/s41467-018-04329-y

M3 - Article

VL - 9

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

IS - 1

M1 - 1983

ER -